Results 101 to 110 of about 58,375 (292)

Molecular theranostics: principles, challenges and controversies

open access: yesJournal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice

open access: yesMolecules, 2018
We developed a bacterial expression system to produce a recombinant disintegrin, vicrostatin (VCN), whose structure is based on a natural disintegrin isolated from southern copperhead snake venom.
Steve Swenson   +5 more
doaj   +1 more source

Data from The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy

open access: gold, 2023
Janik Puttemans   +16 more
openalex   +1 more source

New Bifunctional Chelator 3p-C-NEPA for Potential Applications in Lu(III) and Y(III) Radionuclide Therapy and Imaging [PDF]

open access: gold, 2020
Xiang Sun   +8 more
openalex   +1 more source

Noninvasive PET Imaging and Tracking of Engineered Human Muscle Precursor Cells for Skeletal Muscle Tissue Engineering [PDF]

open access: yes, 2016
Transplantation of human muscle precursor cells (hMPCs) is envisioned for the treatment of various muscle diseases. However, a feasible noninvasive tool to monitor cell survival, migration, and integration into the host tissue is still missing. METHODS:
Ametamey, Simon M.   +10 more
core   +2 more sources

A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 460-473, March 2025.
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Robin Michelet   +8 more
wiley   +1 more source

Radionuclide-labelled nanoparticles for cancer combination therapy: a review

open access: yesJournal of Nanobiotechnology
Radionuclide therapy (RT) is widely used to advanced local cancers. However, its therapeutic efficacy is limited to the radiation resistance of cancer cells.
Na Sun, Tao Wang, Song Zhang
doaj   +1 more source

Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview

open access: yesActa Clinica Croatica
Despite initial response to androgen inhibition, metastatic prostate cancer is invariably an incurable disease. New agents with different mechanisms of action are needed that are capable of producing clinical benefit and prolonging survival.
Antonela Njavro   +7 more
doaj   +1 more source

Cutting‐edge advances in bicyclic peptide‐based radiotracers for cancer imaging and theranostics

open access: yesVIEW, EarlyView.
Abstract Along with successful clinical approval of radiopharmaceuticals targeting somatostatin receptor subtype 2 and prostate‐specific membrane antigen, peptide‐based radiotracers have garnered the increasing attention in cancer imaging and theranostics. As a newly emerging targeting ligand in recent years, bicyclic peptides have demonstrated immense
Hengyi Ou, Xiaobo Wang, Fei Kang
wiley   +1 more source

Home - About - Disclaimer - Privacy